BMJ  2008;336 (19 January), doi:10.1136/bmj.39462.555197.47

Editor's Choice

Absolute risk please

The first 150 words of the full text of this article appear below.

The BMJ has a noble tradition of fighting the trend to medicalise risk factors (BMJ 2002;324:886-91; doi: 10.1136/bmj.324.7342.886). This week we hear more about whether we should be treating women who have "pre-osteoporosis," otherwise known as osteopenia—bone mineral densities that are slightly below normal. These women are at low risk of fracture but are considered by some to be "at risk of being at risk." They comprise more than half of the world’s postmenopausal women.

Pablo Alonso-Coello and colleagues examine four post hoc analyses of trials of osteoporosis drugs that claim to support drug treatment for osteopenia (p 126; doi 10.1136/bmj.39435.656250.AD). They find that the benefits of treatment in these low risk women are overstated and the harms underplayed. They urge clinicians to base treatment decisions on absolute rather than relative risk. It’s a lesson worth repeating: "impressive sounding reductions in relative risk can mask much smaller . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Shifting the focus in fracture prevention from osteoporosis to falls

Teppo L N Järvinen, Harri Sievänen, Karim M Khan, Ari Heinonen, and Pekka Kannus
BMJ 2008 336: 124-126. [Extract] [Full Text] [PDF]

Drugs for pre-osteoporosis: prevention or disease mongering?

Pablo Alonso-Coello, Alberto López García-Franco, Gordon Guyatt, and Ray Moynihan
BMJ 2008 336: 126-129. [Extract] [Full Text] [PDF]

The "problem" junior: whose problem is it?

Yvonne Steinert
BMJ 2008 336: 150-153. [Extract] [Full Text] [PDF]

Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and meta-analysis

S Gates, J D Fisher, M W Cooke, Y H Carter, and S E Lamb
BMJ 2008 336: 130-133. [Abstract] [Full Text] [PDF]

Selling sickness: the pharmaceutical industry and disease mongering • Commentary: Medicalisation of risk factors

Ray Moynihan, Iona Heath, David Henry, and Peter C Gøtzsche
BMJ 2002 324: 886-891. [Extract] [Full Text] [PDF]